Probiotic guidelines published by multiple organizations, including the World Gastroenterology Organisation (WGO), the International Scientific Association for Probiotics and Prebiotics (ISAPP), and the American Nutrition Association, suggest that multi-species or multi-strain formulations are superior to single-strain probiotics.
Single-strain probiotics have limited functionality and are more likely to lead to the development of resistance. In contrast, multi-species or multi-strain probiotics can leverage the unique benefits of each strain, producing a "synergistic effect" with enhanced survivability and more effective, stable functionality. Additionally, the coexistence of multiple strains in the gut can form micro-ecological niches, which help collectively resist the colonization of pathogenic bacteria.
While conducting systematic clinical evidence-based research and multidimensional studies on the efficacy and mechanisms of probiotics, Grand Life Sciences Group continuously innovates and actively develops new probiotic drugs and supplements. The SILIANKANG® product series, a multi-strain probiotic formulation, has been clinically validated over many years and has demonstrated significant benefits in enhancing immune function, protecting the gut, and treating diarrhea, constipation, and indigestion related to intestinal microbiota imbalance.
According to probiotic guidelines, consensus statements, and published evidence from multiple organizations including the World Gastroenterology Organisation (WGO), the International Scientific Association for Probiotics and Prebiotics (ISAPP), and the American Nutrition Association, SILIANKANG® meets all the criteria of a high-quality probiotic.
▪Freeze-drying technology, exclusive vacuum packaging, and full cold chain transportation ensure high biological activity.
▪Resistant to acid and bile, ensuring high survival rates and stable colony counts; exhibits excellent colonization efficiency and long-lasting gut residency.
▪The only four-strain combination probiotic formulation in China, containing the highest number of species and strains.
▪Approved by the National Institute of Food and Drug Control (NIFDC) in China, with confirmed safety and no reported adverse reactions.
▪With over ten years of clinical use and promotion, this exclusively patented product has been recognized in evidence-based guidelines and expert consensus on probiotic use.
Multi-Strain Probiotic Formula & Function
|
SILIANKANG® Four-strain Probiotic Combination (Bifidobacterium-based) |
|
|
Probiotic Strains |
Active Count |
|
Bifidobacterium infantis |
2.7x108 CFU/g |
|
Lactobacillus acidophilus |
4.7x108 CFU/g |
|
Enterococcus faecalis |
6.1x107 CFU/g |
|
Bacillus cereus |
1.5x106 CFU/g |
|
This product contains Bifidobacterium infantis, Lactobacillus acidophilus, Enterococcus faecium and Bacillus cereus, which are part of the normal gut microbiota in healthy individuals. Direct supplementation helps inhibit certain pathogenic bacteria in the intestines, maintain normal intestinal motility, and support a balanced gut microbiota. Bacillus cereus colonizes the intestines and consumes oxygen, creating an anaerobic environment that promotes the growth and reproduction of anaerobic bacteria such as Bifidobacterium. |
|
|
SILIANKANG® Ready-to-Eat Probiotics |
|
|
Patent Strains |
Active Count |
|
Lactobacillus paracasei NSL0201 |
25 Billion CFU/4g |
|
Lactobacillus rhamnosus NSL0401 |
20 Billion CFU/4g |
|
Lactobacillus reuteri NSL0501 |
7.5 Billion CFU/4g |
|
Bifidobacterium animalis NSY0201 |
20 Billion CFU/4g |
|
Other Strains |
|
|
Lactobacillus plantarum LP-66 |
Lactobacillus casei LC-46 |
|
Bifidobacterium longum BL-19 |
Pediococcus acidilactici NSS0302 |
|
Bifidobacterium animalis subsp. lactis BL-82 |
Streptococcus thermophilus NSS0501 |
Synergistic Effect of Multi-Strain Combination
High survival and colonization rates of strains
01
Promote each other's growth and survival
▪Streptococcus thermophilus can remove oxygen to create an anaerobic environment, which is beneficial for the growth and survival of anaerobic bacteria such as Bifidobacterium.
02
Promote mutual adhesion
▪The combination of Lactobacillus bifidum and Lactobacillus rhamnosus can enhance the adhesion ability of both strains to the intestinal mucosa of pigs.
▪The presence of Lactobacillus rhamnosus or Lactobacillus delbrueckii subsp. bulgaricus can increase the adhesion of Bifidobacterium.
03
Inhibition of pathogenic bacteria
▪The combined use of Lactobacillus acidophilus, Bifidobacterium breve, and Propionibacterium freudenreichii significantly enhances their ability to inhibit pathogenic microorganisms.
▪Formulations with combined strains can markedly reduce the adhesion ability of Salmonella,Bacillus, and Escherichia coli.
04
Their distribution in the intestine is complementary to some extent, making it easier to form a bacterial biofilm barrier.
▪Lactobacilli are more abundant in the proximal small intestine, while Bifidobacteria are more prevalent in the colon.
05
Acid & Bile Salt Tolerance of Four Probiotic Strains
All four SILIANKANG®probiotic strains show strong survival at gastric pH levels between 2.5 and 4.5 within three hours. Taking the product within 30 minutes after a meal helps ensure the live bacteria safely transit through the stomach.
When bile salt concentrations range from 0.03% to 0.2%, the changes in the counts of all four live strains remain within the same order of magnitude. Even at a concentration of 0.3%, the variations in viable counts stay within two orders of magnitude, and the survival rates remain relatively good.
Temperature Stability of Four Probiotic Strains
When the storage temperature was at or below 25 ℃, there were no significant differences in the viable counts of the four probiotic strains. At 30 ℃, only the Bacillus subtilis group showed no significant difference, and all groups met or exceeded the national standard. At 35 ℃, significant differences were observed among all strains, and the Lactobacillus acidophilus count fell below the national standard on day 21.
Therefore, SILIANKANG®can be stored for at least 35 days at temperatures of 30 ℃ or below, and for at least 14 days at 35 ℃. It is recommended to store the product away from light.
Cold Chain Transportation
SILIANKANG® Multi-strain Probiotic Blend maintains optimal bioactivity through end-to-end cold chain transportation.
Clinical Research
|
Disease Type |
Article Title |
Publication Date |
Journal |
Research Conclusions |
|
Irritable Bowel Syndrome (IBS) |
The Short-Term Efficacy of Bifidobacterium Quadruple Viable Tablet in Patients With Diarrhea-Predominant Irritable Bowel Syndrome: Potentially Mediated by Metabolism Rather Than Diversity Regulation |
2023 |
The American Journal of GASTROENTEROLOGY |
SILIANKANG®Four-strain Probiotic Combination (Bifidobacterium-based) can increase gut short-chain fatty acid concentrations and improve symptoms of diarrhea predominant irritable bowel syndrome, especially abdominal pain. |
|
Gestational Vomiting |
Internet of things-based design of maternal and infant monitoring system and adoption of gold nanoparticles bacterial DNA detection technology in probiotic treatment of pregnancy reaction |
2022 |
Sustainable Computing: Informatics and Systems |
SILIANKANG®Four-strain Probiotic Combination (Bifidobacterium-based) can reduce the colonization of pathogenic intestinal bacteria in pregnant women and lower the occurrence rate of nausea and vomiting of pregnancy (NVP). |
|
H. pylori Infection |
Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial |
2022 |
Frontiers in Immunology |
The Helicobacter pylori eradication regimen combined with SILIANKANG® Four-strain Probiotic Combination (Bifidobacterium-based) can reduce gastrointestinal adverse reactions and regulate the gastrointestinal microecological flora. |
|
H. pylori Infection |
The impact of Helicobacter pylori infection, eradication therapy,and probiotics intervention on gastric microbiota in young adults |
2021 |
Helicobacter |
Helicobacter pylori eradication can disrupt gastric microbiota balance, while supplementation with SILIANKANG® Four-strain Probiotic Combination (Bifidobacterium-based) may restore the microbial disturbances caused by eradication therapy. |
| Adverse Effects After Colorectal CanGer Surgery | Postoperative Probiotics Administration Attenuates Gastrointestinal Complications and Gut Microbiota Dysbiosis Caused by Chemotherapy in Colorectal Cancer Patients |
2023 |
Nutrients | SILIANKANG® Four-strain Probiotic Combination (Bifidobacterium-based) can restore intestinal microbiota homeostasis and significantly alleviate chemotherapy-induced gastrointestinal complications, including abdominal discomfort and diarrhea. |
| Digestive Endoscopy Recovery | Oral Probiotics Alleviate Intestinal Dysbacteriosis for People Receiving Bowel Preparation | 2020 | Frontiers in Medicine | Supplementation with SILIANKANG® Four-strain Probiotic Combination (Bifidobacterium-based) restores intestinal microbiota imbalance caused by bowel preparation and reduces side effects associated with colonoscopy. |
| Gastrectomy for Gastric Cancer | A randomised trial of probiotics to reduce severity of physiological and microbial disorders induced by partial gastrectomy for patients with gastric cancer |
2019 |
Journal of Cancer | Application of SILIANKANG® Four-strain Probiotic Combination (Bifidobacterium-based) significantly enhances immune function, reduces disease severity, and ameliorates gut microbiota-associated inflammation in patients. |
| Constipation | Efficacy of Bifidobacterium Tetragenous Viable Bacteria Tablets for Cancer Patients with Functional Constipation |
2014 |
Asian Pacific Journal of Cancer Prevention | SILIANKANG® Four-strain Probiotic Combination (Bifidobacterium-based) emonstrate efficacy and safety in managing chemotherapy-induced functional constipation in cancer patients. |
| Immunity | Mechanism of the Immunomodulatory Effect of the Combination of Live Bifidobacterium, Lactobacillus, Enterococcus, and Bacillus onImmunocompromised Rats |
2021 |
Frontiers in Immunology | SILIANKANG® Four-strain Probiotic Combination (Bifidobacterium-based) is a widely used probiotic medication that can significantly reverse immunodeficiency, alleviate systemic inflammation and metabolic disorders, and restore the gut microbiota and metabolic profile in cyclophosphamide treated rats. |
| Chronic Colitis | Probiotic mixtures with aerobic constituent promoted the recovery of multi-barriers in DSS-induced chronic colitis |
2020 |
Life Sciences | SILIANKANG® Four-strain Probiotic Combination (Bifidobacterium-based) helps restore the integrity of the gut microbiota and enhances multiple types of intestinal barrier function. Aerobic Bacillus cereus supports and potentiates the activity of Bacillus infantis, Lactobacillus acidophilus, and Enterococcus faecalis. |
| Ulcerative Colitis (UC) | Bifidobacterium infantis Maintains Genome Stability in Ulcerative Colitis via Regulating Anaphase-Promoting Complex Subunit 7 |
2021 |
Frontiers in Microbiology | SILIANKANG® Four-strain Probiotic Combination (Bifidobacterium-based) can reduce the risk of colitis-associated cancer. |
| Cognitive Disorder | Whole brain radiotherapy induces cognitive dysfunction in mice: key role of gut microbiota |
2020 |
Psychopharmacology | WBRT-induced cognitive impairment is associated with gut microbiota dysbiosis. Supplementation with SILIANKANG® Four-strain Probiotic Combination (Bifidobacterium-based) can improve the gut microbiota and exert beneficial effects on cognitive impairment in individuals exposed to whole brain radiotherapy. |